Comparative Effectiveness of Prophylaxis in Cataract Surgery
Comparative Effectiveness of Prophylaxis in Cataract Surgery
批准号:
8600280
负责人:
LISA J HERRINTON
金额:
$19.4万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-02-01 至 2017-01-31
关键词:
AccountingAdherenceAdoptedAdverse eventAntibioticsAreaCaliforniaCaringCataractCataract ExtractionComputerized Medical RecordConsentControlled StudyDataDay SurgeryDiagnosisDrug CostsEffectivenessEligibility DeterminationEndophthalmitisEyedropsEyelid structureFee-for-Service PlansGenerationsInfectionInjection of therapeutic agentIntraoperative PeriodLinkLocal Anti-Infective AgentsMeasurementMedicareMethodsNursesOperative Surgical ProceduresPatientsPatternPharmacistsPhysiciansPopulationPostoperative PeriodPovidone-IodineProceduresProcessProphylactic treatmentProtocols documentationRandomizedRandomized Controlled TrialsReportingRiskRouteSafetySamplingSavingsSolutionsStatistical MethodsSterilitySurgeonSurgical complicationSystemTopical AntibioticTopical applicationVariantVisionVisual Acuityarmclinical decision-makingclinical practicecomparativecomparative effectivenesscostdesignevidence baseimprovedknowledge basememberprogramsprophylacticpublic health relevancestandardized care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cataract surgery restores sight and is one of the most common surgeries performed. For these reasons, the effectiveness, safety, cost, and accessibility of cataract surgery procedures and therapies are highly significant. Because the evidence base for infection prophylaxis is limited, surgeon practices are highly variable. We propose to conduct a retrospective comparative effectiveness study that will leverage variation in practice among the 297 cataract surgeons providing care to 6.6 million California members of Kaiser Permanente. The study will examine whether the variation in prophylaxis evident among Kaiser Permanente surgeons resulted in differences in infection risk. Recent preliminary data indicate that 71% of surgeons routinely use patient- instilled eye drops before the day of surgery, 26% nurse-instilled eye drops in the pre-op holding area, 13% subconjunctival injection, 30% intracameral injection, and 58% intra-operative eye drops. Nearly all use post- operative eye drops, but there is variation in choice of agent. The study will use these variations
to estimate the comparative and incremental effectiveness of prophylactic strategies. The study will use data recorded into the electronic medical record from 460,000 cataract surgeries performed during 2005-2011, of which 350 infections occurred. We will validate the endophthalmitis diagnosis and surgical complications for 1000 patients (all 350 endophthalmitis cases plus a random sample of 700 non- cases). The study will use instrumental variables to make valid inferences, and each prophylactic procedure will be evaluated individually, while holding constant other prophylactic procedures. The rapid, low-cost study we propose is an essential step to developing the knowledge base for future research. We will use the data to fully articulate the rationale for a randomized controlled trial, including information gaps, priorities, and feasibility, and to build surgeon and pharmacist support. In addition, we will elucidate design trade-offs linked to the unit of randomization and consent process, eligibility and population subsets, the number of study arms, contrasts, the measurement system, protocol adherence, and study power. In addition, the comparative-effectiveness study has a high likelihood of immediately informing clinical decision-making on several key issues, most particularly, prophylaxis before the day of therapy, before any surgical complication could occur. If the level of practice variation in the Medicare fee-for-service program mirrors Kaiser Permanente's, then the excess number of infections could be as large as 2,000 annually. If the study demonstrates that pre-operative antibiotic administrations can be eliminated, we calculate potential savings of ~$70 per case in drug costs alone, totaling $127 million annual savings to Medicare. If it further demonstrates that intra- and post- operative administrations can be switched to the older-generation antibiotics, additional savings would amount to ~$60 per case for a total annual savings to Medicare of $236 million annually.
期刊论文(15)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.ajo.2021.02.007
发表时间:
2021-07
期刊:
American journal of ophthalmology
影响因子:
4.2
作者:
[Shorstein NH, Liu L, Carolan JA, Herrinton L]
通讯作者:
Herrinton L
Intracameral Antibiotics in the Shadow of Hemorrhagic Occlusive Retinal Vasculitis.
出血性闭塞性视网膜血管炎阴影下的前房内抗生素。
DOI:
10.1016/j.ophtha.2017.02.019
发表时间:
2017
期刊:
Ophthalmology
影响因子:
13.7
作者:
[Naseri,Ayman, Melles,RonaldB, Shorstein,NealH]
通讯作者:
Shorstein,NealH
DOI:
10.1016/j.ophtha.2015.08.039
发表时间:
2016-02
期刊:
Ophthalmology
影响因子:
13.7
作者:
[Herrinton LJ, Shorstein NH, Paschal JF, Liu L, Contreras R, Winthrop KL, Chang WJ, Melles RB, Fong DS]
通讯作者:
Fong DS
Failure Modes and Effects Analysis of bilateral same-day cataract surgery.
双侧当日白内障手术的失败模式和效果分析。
DOI:
10.1016/j.jcrs.2016.12.025
发表时间:
2017
期刊:
Journal of cataract and refractive surgery
影响因子:
2.8
作者:
[Shorstein,NealH, Lucido,Carol, Carolan,James, Liu,Liyan, Slean,Geraldine, Herrinton,LisaJ]
通讯作者:
Herrinton,LisaJ
DOI:
10.1016/j.ogla.2020.10.002
发表时间:
2021-05
期刊:
Ophthalmology. Glaucoma
影响因子:
--
作者:
[Carolan JA, Liu L, Alexeeff SE, Amsden LB, Shorstein NH, Herrinton LJ]
通讯作者:
Herrinton LJ
共 7 条
Predicting final visual acuity following cataract surgery
-
批准号:9215348
-
项目类别:
-
资助金额:$36.96万
-
财政年份:2017
-
负责人:LISA J HERRINTON
-
依托单位:
Comparative Effectiveness of Prophylaxis in Cataract Surgery
-
批准号:8428618
-
项目类别:
-
资助金额:$23.83万
-
财政年份:2013
-
负责人:LISA J HERRINTON
-
依托单位:
Psoriasis treatments, cardiovascular disease, and diabetes
-
批准号:8506094
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2013
-
负责人:LISA J HERRINTON
-
依托单位:
Psoriasis treatments, cardiovascular disease, and diabetes
-
批准号:8728163
-
项目类别:
-
资助金额:$24.89万
-
财政年份:2013
-
负责人:LISA J HERRINTON
-
依托单位:
Kaiser Permanente Autoimmune Disease Registry
-
批准号:7815188
-
项目类别:
-
资助金额:$49.97万
-
财政年份:2009
-
负责人:LISA J HERRINTON
-
依托单位:
Kaiser Permanente Autoimmune Disease Registry
-
批准号:7937015
-
项目类别:
-
资助金额:$49.96万
-
财政年份:2009
-
负责人:LISA J HERRINTON
-
依托单位:
HR-QOL in Colorectal Cancer Survivors with Stomas
-
批准号:8296695
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2004
-
负责人:LISA J HERRINTON
-
依托单位:
HR-QOL in Colorectal Cancer Survivors with Stomas
-
批准号:7653542
-
项目类别:
-
资助金额:$44.44万
-
财政年份:2004
-
负责人:LISA J HERRINTON
-
依托单位:
HR-QOL in Colorectal Cancer Survivors with Stomas
-
批准号:8465832
-
项目类别:
-
资助金额:$37.81万
-
财政年份:2004
-
负责人:LISA J HERRINTON
-
依托单位:
HR-QOL in Colorectal Cancer Survivors with Stomas
-
批准号:8069867
-
项目类别:
-
资助金额:$41.92万
-
财政年份:2004
-
负责人:LISA J HERRINTON
-
依托单位:
HR-QOL in Colorectal Cancer Survivors with Stomas
-
批准号:7846882
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2004
-
负责人:LISA J HERRINTON
-
依托单位:
Epidemiology of Marginal Zone Lymphoma
-
批准号:6665485
-
项目类别:
-
资助金额:$7.39万
-
财政年份:2002
-
负责人:LISA J HERRINTON
-
依托单位:
Epidemiology of Marginal Zone Lymphoma
-
批准号:6584697
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2002
-
负责人:LISA J HERRINTON
-
依托单位:
PREVENTIVE ONCOLOGY ACADEMIC AWARDS
-
批准号:6173047
-
项目类别:
-
资助金额:$8.65万
-
财政年份:1996
-
负责人:LISA J HERRINTON
-
依托单位:
PREVENTIVE ONCOLOGY ACADEMIC AWARDS
-
批准号:2114735
-
项目类别:
-
资助金额:$8.38万
-
财政年份:1996
-
负责人:LISA J HERRINTON
-
依托单位:
PREVENTIVE ONCOLOGY ACADEMIC AWARDS
-
批准号:2700679
-
项目类别:
-
资助金额:$9.79万
-
财政年份:1996
-
负责人:LISA J HERRINTON
-
依托单位:
PREVENTIVE ONCOLOGY ACADEMIC AWARDS
-
批准号:2895554
-
项目类别:
-
资助金额:$9.79万
-
财政年份:1996
-
负责人:LISA J HERRINTON
-
依托单位:
PREVENTIVE ONCOLOGY ACADEMIC AWARDS
-
批准号:2414460
-
项目类别:
-
资助金额:$9.79万
-
财政年份:1996
-
负责人:LISA J HERRINTON
-
依托单位:
海外基金